News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mesoblast Limited Interview With MD Silviu Itescu On Angioblast - Progression of Four Phase 2 Trial Applications
September 1, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne, Sep 1, 2009 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) is pleased to provide an interview with MD Silviu Itescu on its United States-based associate company Angioblast Systems Inc.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Asia
Australia
MORE ON THIS TOPIC
Pipeline
Regeneron ends eye disease study due to antibody’s safety profile
August 18, 2026
·
2 min read
·
Tristan Manalac
Metabolic disorders
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
August 18, 2026
·
2 min read
·
Tristan Manalac
Drug Development
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
August 17, 2026
·
3 min read
·
Gabrielle Masson
China
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
August 17, 2026
·
2 min read
·
Annalee Armstrong
